glp-1 and chronic kidney disease agonists in the treatment of in type 2 diabetes obesity GLP-1 Receptor Agonists in the

GLP-1s mimic natural hormones that regulate hunger and slow digestion

They are not recommended during pregnancy or breastfeeding, and women of childbearing potential should use effective contraception

Weight loss and appetite reduction are the expected outcomes of GLP-1 medications 3 , but it is important to lose weight in a healthy manner

Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath

In contrast to other proteins that do not engage FcRn, the two ligands are prevented from progressing to the lysosomes for degradation by binding to the receptor in early sorting endosomes 41,43,47,49,50

Biomarkers including HbA1c, fasting insulin, lipid profiles, and body composition measurements provide the quantitative feedback needed to determine whether the combined approach is producing the intended metabolic effects, whether adjustments to formulation or dosing are needed, and whether the balance between the two therapies remains appropriate as a woman's physiology evolves through and beyond the menopausal transition